New models help predict liver cancer after successful hepatitis C virus (HCV) treatment
(Spink Health) Digital ILC 2020: European scientists develop new predictive models for HCC in patients with chronic HCV after a sustained virological response to direct-acting antiviral therapy (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 26, 2020 Category: Cancer & Oncology Source Type: news
HCV Relapse After Successful Treatment With DAAs HCV Relapse After Successful Treatment With DAAs
HCV recurred in this patient 6 months after achieving SVR with direct-acting antiviral therapy, along with a sarcomatous change in HCC. What might be the relationship between these events?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 15, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Triple Antiviral Therapy Promising for Mild-to-Moderate COVID-19
MONDAY, May 11, 2020 -- For patients with COVID-19, early triple antiviral therapy (lopinavir-ritonavir, ribavirin, and interferon beta-1b) is better than lopinavir-ritonavir for reducing the time to providing a nasopharyngeal swab negative for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 11, 2020 Category: Pharmaceuticals Source Type: news
New triple antiviral drug combination shows early promise for treating COVID-19 in phase 2 randomized trial
A two-week course of antiviral therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin, started within 7 days of showing COVID-19 symptoms, is safe and more effective at reducing the duration of viral shedding than lopinavir-ritonavir alone in patients with mild to moderate illness, according to the first randomised trial of this triple combination therapy involving 127 adults (aged 18 and older) from six public hospitals in Hong Kong. (Source: World Pharma News)
Source: World Pharma News - May 11, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Why Infectious Diseases Like COVID-19 Make Science Move So Fast
This article is part of #TIME100Talks: Finding Hope, a special series featuring leaders across different fields sharing their ideas for navigating the pandemic. Want more? Sign up for access to more virtual events, including live conversations with influential newsmakers. (Source: TIME: Health)
Source: TIME: Health - May 8, 2020 Category: Consumer Health News Authors: Mandy Oaklander Tags: Uncategorized COVID-19 TIME 100 TIME100 Talks video Source Type: news
The Lancet: New triple antiviral drug combination shows early promise for treating COVID-19 in phase 2 randomized trial
(The Lancet) A two-week course of antiviral therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin, started within 7 days of showing COVID-19 symptoms, is safe and more effective at reducing the duration of viral shedding than lopinavir-ritonavir alone in patients with mild to moderate illness, according to the first randomized trial of this triple combination therapy involving 127 adults (aged 18 and older) from six public hospitals in Hong Kong. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 8, 2020 Category: Infectious Diseases Source Type: news
Model Shows Hep C-Infected Kidney Transplants Beneficial, Cost-Effective
MONDAY, April 6, 2020 -- Transplanting hepatitis C virus (HCV)-infected kidneys into uninfected recipients and then treating patients with antiviral therapy leads to a higher quality of life and is less costly than waiting for transplantation with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 6, 2020 Category: Pharmaceuticals Source Type: news
FDA Gives Nod for Breakthrough HIV Test
Vela Diagnostics will go down in history as bringing to market the first test capable of detecting human immunodeficiency virus (HIV) Type-1 drug resistance mutations using next-generation sequencing (NGS) technology.
The Fairfield, NJ-based company submitted the Sentosa SQ HIV Genotyping Assay for FDA market authorization in March. It is the first FDA-authorized HIV drug resistance assay that uses NGS technology.
“The ability to rationally select treatments for patients about to start or already taking antiviral therapy provides another tool in our ongoing ...
Source: MDDI - November 6, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: IVD Source Type: news
' Curing' Hepatitis C Is Not the End of Patient Care'Curing' Hepatitis C Is Not the End of Patient Care
Antiviral therapy has given patients with hepatitis C infection a new lease on life, but the risk for cancer and reinfection means they still require continued monitoring.Medscape Gastroenterology (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - August 12, 2019 Category: Gastroenterology Tags: Gastroenterology Article Source Type: news
Parkinson Disease Incidence Lower in Hep C Patients Who Receive Antivirals
THURSDAY, June 6, 2019 -- The incidence of Parkinson disease (PD) is lower for patients with chronic hepatitis C virus (HCV) infection who receive interferon-based antiviral therapy, according to a study published online June 5 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 6, 2019 Category: Pharmaceuticals Source Type: news
Discarded No More: HCV-Infected Organs Advance Transplantation Discarded No More: HCV-Infected Organs Advance Transplantation
Direct-acting antiviral therapy has made the use of HCV-infected organs a reality. Here is an inside look at one liver transplant program as they deliberate this option for their patients.Medscape Gastroenterology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 3, 2019 Category: Allergy & Immunology Tags: Gastroenterology Commentary Source Type: news
Antiviral therapy improves survival rates for kidney transplant recipients with hepatitis B or C
(Elsevier) Prior to the development of antiviral therapy, kidney transplant recipients infected with either hepatitis B (HBV) or hepatitis C (HCV) experienced poor outcomes. In a new study in the Journal of Hepatology, published by Elsevier, researchers report favorable 10-year survival rates for patients with HBV and/or HCV treated with antiviral agents and advise that antiviral therapy should be systematically offered to all HBV and HCV patients in line with international recommendations. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 14, 2019 Category: Infectious Diseases Source Type: news
Early Antiviral Therapy and Lymphoma Risk in Chronic HCV Early Antiviral Therapy and Lymphoma Risk in Chronic HCV
Chronic HCV infection has been linked to lymphoproliferative disorders. Can early PegIFN/RBV therapy reduce the risk?Alimentary Pharmacology & Therapeutics (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 13, 2019 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news
Liver Transplant Listing for HCV-associated Cirrhosis and HCC Liver Transplant Listing for HCV-associated Cirrhosis and HCC
How has the availability of direct-acting antiviral therapy impacted liver transplantation indications and waiting list outcomes in patients with chronic hepatitis C?Journal of Viral Hepatitis (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 6, 2019 Category: Transplant Surgery Tags: Gastroenterology Journal Article Source Type: news
Stopping Oral Antiviral Therapy in Chronic Hep B Possible for Some People Stopping Oral Antiviral Therapy in Chronic Hep B Possible for Some People
A new analysis provides insight into what happens after stopping tenofovir disoproxil fumarate (TDF) in chronic hepatitis B patients with persistent viral suppression who took the drug for at least eight years.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 1, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news
